Functionality development and registration
- Selection of software vendors
- Definition of software content
- Management of milestones and deliverables
Reimbursement
- Medical impact calculation
- Economic impact calculation
- Payor identification and negotiation
Digital Health Trial
- Trial design concept
- Patient identification
- Trial conduction
- Real world evidence generation
Scaling
- Pricing strategy and market access
- International payor negotiation
- Global medical network activation
- Ideation
- Business model evaluation
- Reimbursement forecast
- Prototype concept
- Selection of software vendors
- Definition of software content
- Management of milestones and deliverables
- Medical impact calculation
- Economic impact calculation
- Payor identification and negotiation
- Trial design concept
- Patient identification
- Trial conduction
- Real world evidence generation
- Pricing strategy and market access
- International payor negotiation
- Global medical network activation
- Leading Medtech device company with the goal to establish a Digital Health functionality to support orthopaedic patients both inside and outside of medical facilities (remote care). No experience in Digital Health, but a strategic goal to support product sales through Digital Health.
- Syte process support platform (guided through the optimal indications and product positioning for maximised impact of the market access)
- Syte analytical engine (integrated data from scientific publications, internal data and data from first tests inside medical institutions)
- Remote care functionality definition for optimal aftercare support (selection of optimal orthopaedic indications for reimbursement planning)
- Definition of the medical and economic impact model and the according pricing scheme for the Digital Health service
- Product and Digital Health service sales growth concept
- Definition of a draft on the Digital Health infrastructure of the “intelligent” orthopaedic digital health product service for major payors (public and private insurers)
- Stakeholder interviews (payers and potential healthcare providers) about the Digital Health service covering general feedback and perceived added value of the digital solution
- Framework for calculation of the medical and economic impact of the Digital Health services (e.g. impact on quality of treatment, quality of life, time and cost savings in various levels, real procedure costs before and after, etc.)
- Challenging this medical and economic impact framework regarding expected process and organisational changes with data from a medical partner institution
- Definition of the expected medical and economic impact model based on the aggregated data as the hypothesis for reimbursement negotiations with key stakeholders (e.g. health insurers)
- Leading hearing implant device company intends to establish Digital Health functionalities to support lifelong aftercare. Only limited experience in Digital Health, but large internal IT-team.
- A pharmaceutical multinational targets increased usage of an expensive antiarrythmic drug. As the prescription is very challenging for physicians (medical and economic barriers), a decision support tool application for medical professionals seemed to be helpful.
- Subgroup analysis with largest medical benefit. The analysis is based on publications and internal databases of leading university hospitals
- Economic forecast of cost savings based on medical subgroup analysis
- Concept for a patient selection algorithm that identifies those patients with the largest medical and economic impact
- Software development and medical product class registration
- Retrograde validation and optimisation of this algorithm on an internal hospital database
- Implementation of the decision support tool within the respective medical departments
Securing Global Reimbursement: Tailored Market Access for Asthma/COPD Medication and Digital Solutions
- One of the largest generic pharmaceutical firms with a specific product and digital service for Asthma/COPD patients and the goal to achieve global market access and reimbursement for the pharmaceutical product and digital health component
- Syte process support platform (guided through the market access process within different countries)
- Syte analytical engine (integrated data from scientific publications, internal data, patient selection for first tests, outcome evidence collection)
- Country specific road to market / pathway to launch the pharmaceutical product and digital service with according reimbursement
- Country specific medical and economic benefit calculations and performance assessment frameworks
- Reimbursement pricing including the core pharmaceutical product and digital health service inside and outside the European Union
- Selection of optimal launch markets based on Syte databases (market data, e.g., population size, per capita spending, Digital Health readiness, payor goals, government strategies, unmet needs (e.g. lack of physician or nursing resources), further windows of opportunities)
- Definition of main stakeholders to be approached (regional governmental institutions, payors, healthcare providers) for first roll out
- Data generation plan to further strengthen the negotiation basis for payor discussions
- Tailoring of a medical and economic impact model to the country specific framework conditions and according to the feedback of payors
- Development of country specific economic performance assessments to implement reimbursement